Abstract P45: REDUCED IMMUNOGENICITY DRIVES SUPERIORITY OF THE NANOLUCIFERASE (NLUC) REPORTER IN AN IMMUNOCOMPETENT GL261 MOUSE GLIOMA MODEL

Résumé fourni par la source

Abstract Bioluminescence imaging (BLI) with luciferase-based reporters is a robust approach for monitoring tumour growth and treatment response in preclinical in vivo cancer models. Luciferases are considered foreign molecules that could elicit immune responses when introduced in immunocompetent live animal models [1, 2]. The immunogenicity of luciferases and other transgenic imaging reporters, though often overlooked, was recently discussed in relation to mouse cancer models [3-5]. Herein, we investigated the immunogenicity of two luciferase reporters: (1) red-shifted firefly luciferase (RFLuc, 61 kDa) and (2) deep-sea shrimp nanoluciferase (nLuc, 19 kDa) in an orthotopic brain tumour model using GL261 mouse glioma cells in a syngeneic C57BL/6J mouse. We evaluated their suitability for monitoring of brain tumour growth kinetics by BLI. Mice were implanted with 2 × 104 either GL261, GL261-NLuc or GL261-RFLuc cells in the right cerebrum using a stereotaxic device. GL261-RFLuc tumours could only be detected by BLI for 2 weeks, and the mice did not die of disease (median overall survival; mOS > 35 days). In contrast, GL261-nLuc cells formed lethal brain tumours that grew in volume as determined by BLI. GL261-NLuc implanted mice exhibited mOS comparable to mice implanted with GL261 cells (24.5 days vs. 23 days). These observations indicated that nLuc is not significantly immunogenic in mouse brains and did not cause rejection of the tumour cells as observed with RFluc. Cytokine expression profiles and immune cell profiles of the tumour-bearing brain hemispheres were comparable between tumours from GL261 and GL261-NLuc. In contrast, GL261-RFLuc tumours exhibited elevated CD8+ T cells, particularly effector (CD62L¯CD44+) and granzyme B-expressing (GZB+) CD8+ T cells. GL261-nLuc formed stable glioma tumors comparable to the original GL261 mouse model and is a suitable in vivo preclinical model for evaluating experimental therapeutic interventions against gliomas, when paired with Promega’s proprietary fluoro-furimazine substrate. Funding: This research was supported by Singapore’s Health and Biomedical Sciences (HBMS) Industry Alignment Fund Pre-Positioning (IAF-PP) grant H18/01/a0/018 (to AMC) administered by A*STAR and Singapore-MIT Alliance for Research and Technology (SMART) Innovation Grant (ING-000913 BIO) (to AMC). Citation Format: Carla Bianca Luena Victorio, Wisna Novera, Arun Ganasarajah, Joanne Ong, Peter Li, Sven Hans Petersen, Rasha Msallam, Ann-Marie Chacko. REDUCED IMMUNOGENICITY DRIVES SUPERIORITY OF THE NANOLUCIFERASE (NLUC) REPORTER IN AN IMMUNOCOMPETENT GL261 MOUSE GLIOMA MODEL [abstract]. In: Proceedings of Frontiers in Cancer Science; 2023 Nov 6-8; Singapore. Philadelphia (PA): AACR; Cancer Res 2024;84(8_Suppl):Abstract nr P45.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.